Ankle replacement surgeries have grown over the last decade, and according to Musculoskeletal Clinical Regulatory Advisors, as of February 2011 all public insurance programs, workers compensation and 92% of commercial insured patients have access to ankle replacement procedures when deemed medically necessary by a trained surgeon.1
For more information, visit djoglobal.com/TrilliantSurgical
1. SmartTrak® Foot & Ankle Reimbursement: https://app.smarttrak.com/markets/qs/fd52946dc2bd8b02ac1002535b62cf35
England & Company served as exclusive financial advisor to the sellers.
DJO, a subsidiary of Colfax Corporation (NYSE: CFX), is a leading developer and distributor of high-quality medical devices that provide proven solutions for musculoskeletal health, joint reconstruction, vascular health, and pain management. The Company’s extensive range of products and integrated technologies address the orthopedic continuum of care from performance and mobility to surgical intervention and post-operative rehabilitation; enabling people around the world to regain or maintain their natural motion. For additional information about DJO, please visit www.DJOGlobal.com.
This press release may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning DJO’s plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on DJO’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause DJO’s results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including actions by governments, businesses and individuals in response to the situation, such as the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions, the impact on creditworthiness and financial viability of customers, and other impacts on DJO’s business and ability to execute business continuity plans, and the other factors detailed in Colfax’s reports filed with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Colfax’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. DJO disclaims any duty to update the information herein.
Brittany Knudson
Brittany.knudson@djoglobal.com
760.681.7785
Mike Macek
Colfax Corporation
investorrelations@colfaxcorp.com
302.252.9129
To read the original press release, please click here
Comments